[Featured Stock] Antrogen Hits 52-Week Low

[Asia Economy Reporter Hwang Junho] Antrogen has been plummeting for two consecutive trading days following the failure to meet efficacy in the Phase 3 clinical trial of a diabetic foot ulcer treatment.

As of 10:11 AM on the 24th, Antrogen was trading at 299,550 KRW, down 27.75% from the previous trading day, hitting a 52-week low.

On the 21st, Antrogen announced that it failed to meet the primary efficacy endpoint in the Phase 3 clinical trial (DFU-301) for a diabetic foot ulcer treatment conducted in South Korea.

Antrogen set the safe recovery of the ulcerated wound area as the primary efficacy endpoint, but no significant efficacy difference was demonstrated between the treatment group and the control group.